Jasper Therapeutics, Inc. JSPR
We take great care to ensure that the data presented and summarized in this overview for Jasper Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JSPR
View all-
Velan Capital Investment Management LP Alpharetta, GA11.2MShares$252 Million9.16% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT9.87MShares$222 Million1.01% of portfolio
-
Qiming U.S. Ventures Management, LLC8.52MShares$191 Million9.0% of portfolio
-
Abingworth LLP London, X05.63MShares$126 Million0.9% of portfolio
-
Octagon Capital Advisors LP New York, NY4.47MShares$100 Million0.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.09MShares$91.8 Million0.0% of portfolio
-
Opaleye Management Inc. Boston, MA3.99MShares$89.4 Million1.0% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY3.66MShares$82.1 Million2.47% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY3.54MShares$79.4 Million0.37% of portfolio
-
Bank Of America Corp Charlotte, NC3.18MShares$71.4 Million0.0% of portfolio
Latest Institutional Activity in JSPR
Top Purchases
Top Sells
About JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Insider Transactions at JSPR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
900
-3.47%
|
$23,400
$26.44 P/Share
|
|
Mar 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+3.36%
|
$6,300
$7.1 P/Share
|
|
Feb 08
2024
|
Carlyle Group Inc. |
BUY
Open market or private purchase
|
Indirect |
190,000
+15.13%
|
$2,280,000
$12.95 P/Share
|
|
Feb 08
2024
|
Velan Capital Investment Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
350,000
+22.75%
|
$4,200,000
$12.95 P/Share
|
|
Nov 28
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+16.67%
|
$0
$0.65 P/Share
|
|
Nov 21
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+20.0%
|
$0
$0.64 P/Share
|
|
Nov 20
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+25.0%
|
$0
$0.63 P/Share
|
|
Nov 17
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$0
$0.6 P/Share
|
|
Nov 16
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$0
$0.6 P/Share
|
|
Oct 13
2023
|
William Lis Director |
SELL
Open market or private sale
|
Direct |
7,965
-12.95%
|
$0
$0.85 P/Share
|
|
Oct 12
2023
|
Ron Martell President, CEO and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
87,531
-20.9%
|
$0
$0.85 P/Share
|
|
Oct 12
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,126
-12.93%
|
$0
$0.85 P/Share
|
|
Jun 13
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,000
-3.04%
|
$9,000
$1.66 P/Share
|
|
Jun 13
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+2.95%
|
$0
$0.71 P/Share
|
|
Apr 14
2023
|
Anna Louise French Director |
SELL
Open market or private sale
|
Direct |
7,000
-22.76%
|
$7,000
$1.48 P/Share
|
|
Apr 13
2023
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Direct |
9,075
-30.0%
|
$9,075
$1.49 P/Share
|
|
Apr 13
2023
|
William Lis Director |
SELL
Open market or private sale
|
Direct |
8,500
-12.15%
|
$8,500
$1.44 P/Share
|
|
Apr 12
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,126
-11.45%
|
$37,126
$1.46 P/Share
|
|
Apr 12
2023
|
Ron Martell President, CEO and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
87,531
-17.29%
|
$87,531
$1.46 P/Share
|
|
Jan 27
2023
|
Qiming U.S. Healthcare Fund Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,666,666
+23.84%
|
$2,666,666
$1.5 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 590K shares |
|---|---|
| Exercise of conversion of derivative security | 9.9K shares |
| Payment of exercise price or tax liability | 125K shares |
|---|---|
| Open market or private sale | 17.9K shares |